Updates
** Shares of generic drugmaker Viatris VTRS.O rise as much as 10.1% to a near two-month high of $9.47
** VTRS posts Q1 adj. profit of 50 cents per share, compared with analysts' estimate of 49 cents per share, according to data compiled by LSEG
** Co reports Q1 revenue of $3.25 billion vs estimates of $3.23 billion
** VTRS expects 2025 adj. profit between $2.12 and $2.26 per share, compared with estimate of $2.59 per share
** Co says "it continues to explore ways to optimize the flexibility of our global network, including the potential to increase our manufacturing capacity in the U.S." as a way to mitigate potential tariffs
** Separately, VTRS also says its fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, and a lower dose version of its birth control patch, called Xulane, also met all the main goals of a late-stage study
** Including session's move, stock down 25.3%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.